Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock ...

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea ...

Therapeutics Market, valued at approximately USD 143.95 billion in 2023, is projected to witness strong expansion over the forecast period, reaching an estimated valuation exceeding USD 270 billion by ...

It’s understandable. When the path ahead is unclear, the instinct is to pause. To wait.

GLP-1 drugs have been compared to the discovery of penicillin, which changed the course of medicine by treating several ...

According to Research by SNS Insider, The U.S. GLP-1 Receptor Agonist Market to Reach USD 113.13 Billion by 2032, Driven by Rising Prevalence of Type 2 Diabetes and Demand for Obesity-Related ...

Eli Lilly's stock price shot up by 2.89% on a massive trading volume of 21.27 billion, signaling strong investor interest.

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...